title: [Anti RS virus drugs].
abstract: Palivizumab is one of the monoclonal antibodies for RS virus(RSV), and has been widely used to preterm infants, infants with bronchopulmonary dysplasia, and infants with congenital heart disease. Palivizumab can reduce admission rate and length of hospital stay due to lower respiratory tract infection by RSV. Palivizumab can also reduce the rate of later recurrent wheezing. Motavizumab, the 2nd generation monoclonal antibody, has 18-fold greater neutralizing capacity to RSV. Clinical trials of motavizumab finished, however, motavizumab has not been granted because of skin complication. In anti RSV drugs, ribavirin administration is not recommended because the effect is unclear. Clinical trials of some new anti RSV drugs and two live attenuated intranasal vaccines are underway.
authors.affiliation: Department of Pediatrics, Dokkyo Medical University.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Suzumura
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy; D012136:Respiratory Syncytial Viruses / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D000998:Antiviral Agents